Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription


1 Ann Oncol
1 Ann Surg Oncol
3 Ann Thorac Surg
6 Anticancer Res
2 Arch Bronconeumol
5 BMC Cancer
1 Cancer Lett
1 Cancer Sci
2 Clin Cancer Res
1 Clin Lung Cancer
1 Eur J Cancer
3 Eur J Cardiothorac Surg
1 Eur Respir J
2 Int J Oncol
3 J Thorac Oncol
4 Lung Cancer
2 Mol Cancer Ther
3 Oncologist
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Oncol

  1. CORTIULA F, Reymen B, Peters S, Van Mol P, et al
    Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches.
    Ann Oncol. 2022 Jun 28. pii: S0923-7534(22)01742.
    PubMed         Abstract available

    Ann Surg Oncol

  2. CUI C, Lian B, Zhang X, Wu D, et al
    An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.
    Ann Surg Oncol. 2022 Apr 9. pii: 10.1245/s10434-022-11670.
    PubMed         Abstract available

    Ann Thorac Surg

  3. SUBRAMANIAN MP, Yang Z, Chang SH, Willis D, et al
    Minimum Volume Standards for Surgical Care of Early-Stage Lung Cancer: A Cost-Effectiveness Analysis.
    Ann Thorac Surg. 2022 Jun 30. pii: S0003-4975(22)00899.
    PubMed         Abstract available

  4. ARCHER MA, Martin LW
    Lymph Node Assessment in Lung Cancer - New Practice Standards.
    Ann Thorac Surg. 2022 Jul 3. pii: S0003-4975(22)00928.

  5. MUSLIM Z, Stroever S, Razi SS, Poulikidis K, et al
    Increasing Time-to-treatment for Lung Cancer: Are we going backwards?
    Ann Thorac Surg. 2022 Jun 30. pii: S0003-4975(22)00860.
    PubMed         Abstract available

    Anticancer Res

  6. SHAM NO, Zhao L, Zhu Z, Roy TM, et al
    Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets.
    Anticancer Res. 2022;42:3275-3284.
    PubMed         Abstract available

  7. NAKANO T, Yasumatsu R, Hashimoto K, Kuga R, et al
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
    Anticancer Res. 2022;42:3653-3664.
    PubMed         Abstract available

  8. WU MF, Chen LH, Hsia NY, Shen YC, et al
    Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese.
    Anticancer Res. 2022;42:3381-3387.
    PubMed         Abstract available

  9. KIM YJ, Hong SE, Jang SK, Park KS, et al
    Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition.
    Anticancer Res. 2022;42:3475-3481.
    PubMed         Abstract available

  10. SATO J, Nakano K, Shimizu T, Uchida M, et al
    Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
    Anticancer Res. 2022;42:3575-3582.
    PubMed         Abstract available

  11. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed         Abstract available

    Arch Bronconeumol

  12. RODRIGUEZ PRIDA J, Castano de Las Pozas G, Rugeles Nino J
    Spontaneous Pneumomediastinum, Pneumopericardium, and Pneumoperitoneum in a Patient With Lung Cancer.
    Arch Bronconeumol. 2022 Jun 20. pii: S0300-2896(22)00448.

  13. MENDOZA FERRADAS FJ, Ezponda A, Juan-Aracil GR, Bastarrika G, et al
    Pulmonary Artery Sarcoma: Value of Dual-Energy CT (DECT)-Based Iodine Quantification on Multimodality Workup.
    Arch Bronconeumol. 2022;58:565.

    BMC Cancer

  14. LIU L, Liu J, Deng X, Tu L, et al
    A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma.
    BMC Cancer. 2022;22:715.
    PubMed         Abstract available

  15. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Calvo V, et al
    Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
    BMC Cancer. 2022;22:732.
    PubMed         Abstract available

  16. DUFRAING K, Van Casteren K, Breyne J, D'Haene N, et al
    Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders.
    BMC Cancer. 2022;22:736.
    PubMed         Abstract available

  17. MEI J, Jiang G, Chen Y, Xu Y, et al
    HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
    BMC Cancer. 2022;22:738.
    PubMed         Abstract available

  18. OTSUKA T, Nishida S, Shibahara T, Temizoz B, et al
    CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
    BMC Cancer. 2022;22:744.
    PubMed         Abstract available

    Cancer Lett

  19. LI J, Zhang Q, Jiang D, Shao J, et al
    CircRNAs in lung cancer- role and clinical application.
    Cancer Lett. 2022 Jun 30:215810. doi: 10.1016/j.canlet.2022.215810.
    PubMed         Abstract available

    Cancer Sci

  20. MIYAKAWA K, Miyashita N, Horie M, Terasaki Y, et al
    ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
    Cancer Sci. 2022 Jul 5. doi: 10.1111/cas.15481.
    PubMed         Abstract available

    Clin Cancer Res

  21. FEBRES ALDANA CA, Chang JC, Ptashkin R, Wang Y, et al
    Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset.
    Clin Cancer Res. 2022 Jul 6. pii: 706889. doi: 10.1158/1078-0432.CCR-22-1115.
    PubMed         Abstract available

  22. BARLESI F, Tomasini P, Karimi M, Michiels S, et al
    Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
    Clin Cancer Res. 2022 Jul 8. pii: 706925. doi: 10.1158/1078-0432.CCR-22-0371.
    PubMed         Abstract available

    Clin Lung Cancer

  23. CARDONA AF, Ruiz-Patino A, Recondo G, Martin C, et al
    Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Clin Lung Cancer. 2022 Jun 6. pii: S1525-7304(22)00127.
    PubMed         Abstract available

    Eur J Cancer

  24. TAKADA K, Buti S, Bersanelli M, Shimokawa M, et al
    Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.
    Eur J Cancer. 2022;172:199-208.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  25. TAKAMORI S, Oizumi H, Suzuki J, Watanabe H, et al
    Thoracoscopic anatomical individual basilar segmentectomy.
    Eur J Cardiothorac Surg. 2022;62.
    PubMed         Abstract available

  26. WILLIAMS NR, Patrick H, Fiorentino F, Allen A, et al
    Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) randomized controlled trial: a systematic review of published responses.
    Eur J Cardiothorac Surg. 2022;62.
    PubMed         Abstract available

  27. KAMIGAICHI A, Aokage K, Katsumata S, Ishii G, et al
    Prognostic Impact of Examined Mediastinal Lymph Node Count in Clinical N0 Non-Small Cell Lung Cancer.
    Eur J Cardiothorac Surg. 2022 Jul 4. pii: 6628585. doi: 10.1093.
    PubMed         Abstract available

    Eur Respir J

  28. CROSBIE PAJ, Gabe R, Simmonds I, Hancock N, et al
    Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00483-2022.
    PubMed         Abstract available

    Int J Oncol

  29. ZHANG J, Li J, Li S, Zhou C, et al
    [Retracted] miR802 inhibits the aggressive behaviors of nonsmall cell lung cancer cells by directly targeting FGFR1.
    Int J Oncol. 2022;61.
    PubMed         Abstract available

  30. NIAN R, Jiang H, Zhao J, Hou W, et al
    Differences in actionable genomic alterations between brain metastases and nonbrain metastases in patients with nonsmall cell lung cancer.
    Int J Oncol. 2022;61.
    PubMed         Abstract available

    J Thorac Oncol

  31. XIONG A, Ren S, Liu H, Miao L, et al
    Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00327.
    PubMed         Abstract available

  32. VOTH PARK J, Chandra R, Cai L, Ganguly D, et al
    Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00315.
    PubMed         Abstract available

  33. HIGASHIYAMA RI, Yoshida T, Yagishita S, Ohuchi M, et al
    Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer.
    J Thorac Oncol. 2022 Jul 1. pii: S1556-0864(22)00314.
    PubMed         Abstract available

    Lung Cancer

  34. FROST N, Roeper J, Velthaus JL, Raspe M, et al
    Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
    Lung Cancer. 2022;170:165-175.
    PubMed         Abstract available

  35. WEVER BMM, Bach S, Tibbesma M, Ter Braak TJ, et al
    Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: A feasibility study.
    Lung Cancer. 2022;170:156-164.
    PubMed         Abstract available

  36. WO Y, Li H, Zhang Y, Peng Y, et al
    The impact of station 4L lymph node dissection on short-term and long-term outcomes in non-small cell lung cancer.
    Lung Cancer. 2022;170:141-147.
    PubMed         Abstract available

  37. JIA X, Chu X, Jiang L, Li Y, et al
    Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84].
    Lung Cancer. 2022 Jun 29. pii: S0169-5002(22)00537.

    Mol Cancer Ther

  38. DU Y, Chen Y, Wang Y, Chen J, et al
    HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
    Mol Cancer Ther. 2022;21:1060-1066.
    PubMed         Abstract available

  39. MARTIN AL, Anadon CM, Biswas S, Mine JA, et al
    Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.
    Mol Cancer Ther. 2022;21:1184-1194.
    PubMed         Abstract available


  40. JAHANZEB M, Lin HM, Wu Y, Zhang P, et al
    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Oncologist. 2022 Jul 4. pii: 6628677. doi: 10.1093.
    PubMed         Abstract available

  41. SAKURADA T, Nokihara H, Koga T, Zamami Y, et al
    Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Oncologist. 2022;27:e554-e560.
    PubMed         Abstract available

  42. WANG J, Martin-Romano P, Cassier P, Johnson M, et al
    Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
    Oncologist. 2022;27:536-e553.
    PubMed         Abstract available

    PLoS One

  43. CASTAGNOLI F, Doran S, Lunn J, Minchom A, et al
    Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
    PLoS One. 2022;17:e0270950.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.